Church of PeptidesSearch
Semaglutide · Chapter 1 of 6

Before I had a name

Laboratory work · Reported 2015

How do you make a short-lived signal last?

Fictional scene

Subject One sits beneath a clock that seems determined to hurry him along. Doctide changes the appointment card again. “We need the signal to stay long enough to do its job.” Subject One puts his coat back down. Apparently, this will not be a quick visit.

What changes here

Researchers redesigned GLP-1 for longer action while retaining receptor activity. Clinical studies still had to test its usefulness. [1]

Read the study details & dates
Published 2015

Making a signal last

Researchers modified human GLP-1 to resist enzymatic breakdown and bind albumin while retaining receptor activity. Laboratory binding and signaling tests helped characterize the candidate. This was molecular design, not a clinical benefit demonstration. [1]

What this does not establish

The discovery paper appeared after clinical development was already under way. Its publication year is not an established invention date. This chapter represents laboratory design; Subject One was not a human participant in a cell assay.

Original sources
  1. Lau et al., discovery of once-weekly semaglutide (2015)

Sources reviewed 2026-10-11. Study and publication dates are stated separately where known.

Up next
What happens when promising science raises a warning?

Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story